Dr. Sabashini Ramchand, an endocrinologist and research fellow at Cleveland Clinic, provides specialized care for diabetes and metabolic conditions [1].

Her work focuses on the intersection of hormonal imbalances and long-term bone health, which is critical for patients managing chronic endocrine diseases. Because metabolic disorders often impact skeletal density, her research aims to optimize treatment sequences for patients at risk of fractures.

Based in Cleveland, Ohio, Dr. Ramchand operates within the endocrine unit of the Cleveland Clinic [1]. Her clinical focus includes the management of diabetes and various metabolic disorders that affect the body's hormone production, and regulation [1].

Beyond direct patient care, Dr. Ramchand contributes to medical research regarding bone health therapies. One area of her research involves the use of zoledronic acid to maintain bone mineral density gains following combination therapy with teriparatide and denosumab [2]. This research addresses the volatility of bone density after certain treatments are stopped.

Regarding the risks of stopping specific bone therapies, Dr. Ramchand said, "Discontinuation of denosumab results in high-turnover bone loss and increased fracture risk" [2]. This finding underscores the importance of carefully planned transition therapies to prevent sudden skeletal degradation.

Cleveland Clinic promotes her expertise through its provider tools to help patients find specialists in metabolic health [1]. Her dual role as a clinician and research fellow allows her to apply emerging data on bone mineral density directly to patient care strategies in the U.S. [1].

“"Discontinuation of denosumab results in high-turnover bone loss and increased fracture risk"”

The focus on sequential therapy in bone health indicates a shift toward personalized, long-term maintenance in endocrinology. By identifying the risks associated with the discontinuation of specific drugs like denosumab, researchers are developing protocols to ensure that gains in bone density are not lost, reducing the overall incidence of fractures in aging or metabolically compromised populations.